Chrysalis BioTherapeutics
Chrysalis BioTherapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing regenerative drugs that utilize natural processes to activate endothelial and stem cells, aiming to accelerate tissue repair and improve lives. The company focuses on treatments for serious respiratory disorders, radiation exposure, diabetic foot ulcers, and related medical conditions, with a mission to help improve people's lives through innovation. They are actively involved in clinical trials exploring the efficacy of their lead compound, Chrysalin (TP508), for tissue repair and regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Chrysalis BioTherapeutics
Products
Investigational regenerative thrombin‑derived peptide therapeutic (23‑amino‑acid peptide)
An investigational short peptide developed to stimulate endothelial and progenitor cell‑mediated tissue repair; evaluated preclinically and clinically for wound healing, musculoskeletal repair, ARDS, and radiation countermeasure indications.
TP508
A novel peptide drug product that reduces radiation therapy-induced neural inflammation and restores neural stem cells in the hippocampus of the brain, potentially mitigating radiation-induced brain damage and preventing cognitive impairment.
TP508 (Chrysalin®, rusalatide acetate)
TP508 is an injectable synthetic peptide drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation. It activates stem cells to regenerate tissues and restore function, showing potential efficacy where previous drugs have failed. It is GMP manufactured and has demonstrated safety and efficacy in clinical trials for diabetic foot ulcers and fracture repair.
Chrysalin®
Chrysalin is a regenerative peptide drug initially developed for its wound healing properties, shown to significantly increase the complete healing of chronic ulcers in diabetic foot ulcer human clinical trials. It is being evaluated for the treatment of Cutaneous Radiation Injury (CRI) and Acute Respiratory Distress Syndrome (ARDS).
Investigational regenerative thrombin‑derived peptide therapeutic (23‑amino‑acid peptide)
An investigational short peptide developed to stimulate endothelial and progenitor cell‑mediated tissue repair; evaluated preclinically and clinically for wound healing, musculoskeletal repair, ARDS, and radiation countermeasure indications.
TP508
A novel peptide drug product that reduces radiation therapy-induced neural inflammation and restores neural stem cells in the hippocampus of the brain, potentially mitigating radiation-induced brain damage and preventing cognitive impairment.
TP508 (Chrysalin®, rusalatide acetate)
TP508 is an injectable synthetic peptide drug used to mitigate vascular damage, hemorrhage, and inflammation observed in ARDS induced by viral infection (COVID19) or nuclear radiation. It activates stem cells to regenerate tissues and restore function, showing potential efficacy where previous drugs have failed. It is GMP manufactured and has demonstrated safety and efficacy in clinical trials for diabetic foot ulcers and fracture repair.
Chrysalin®
Chrysalin is a regenerative peptide drug initially developed for its wound healing properties, shown to significantly increase the complete healing of chronic ulcers in diabetic foot ulcer human clinical trials. It is being evaluated for the treatment of Cutaneous Radiation Injury (CRI) and Acute Respiratory Distress Syndrome (ARDS).
Services
Design and execution of in vitro and in vivo studies to evaluate efficacy, endothelial/vascular effects, and mechanisms of peptide therapeutics in radiation and lung injury models.
Regulatory support, IND preparation, management of GLP/nonclinical studies and coordination with agencies for medical countermeasure and pulmonary indications.
Assay development, clinical formulation, and planning for large‑scale manufacturing to support clinical safety/PK and pivotal studies.
Partnerships and contract execution with federal agencies for development of therapeutics as medical countermeasures and for infectious/respiratory indications.
Design and conduct of early‑phase clinical trials (Phase I/II) for wound healing and tissue repair indications, including randomized placebo‑controlled study designs and clinical outcome assessments.
Design and execution of in vitro and in vivo studies to evaluate efficacy, endothelial/vascular effects, and mechanisms of peptide therapeutics in radiation and lung injury models.
Regulatory support, IND preparation, management of GLP/nonclinical studies and coordination with agencies for medical countermeasure and pulmonary indications.
Assay development, clinical formulation, and planning for large‑scale manufacturing to support clinical safety/PK and pivotal studies.
Partnerships and contract execution with federal agencies for development of therapeutics as medical countermeasures and for infectious/respiratory indications.
Design and conduct of early‑phase clinical trials (Phase I/II) for wound healing and tissue repair indications, including randomized placebo‑controlled study designs and clinical outcome assessments.
Expertise Areas
- Peptide therapeutic development
- Preclinical in vivo efficacy studies and animal model development
- Medical countermeasure development for radiation exposure
- Endothelial and vascular biology related to tissue repair
Key Technologies
- Thrombin‑derived peptide therapeutics
- In vivo radiation and ARDS animal models
- Endothelial function assays (NO production, tube formation, sprouting)
- DNA damage and repair assays (γ‑H2AX foci quantification)
News & Updates
Chrysalis was selected to participate in the 2024 Respiratory Innovation Summit at the American Thoracic Society Meeting.
The FDA has approved Chrysalis to begin human clinical trials for Chrysalin™ (TP508) for treating acute lung failure.
Fife C, Mader JT, Stone J, Brill L, Satterfield K, Norfleet A, Zwernemann A, Ryaby JT, Carney DH. Wound Repair Regen. 2007 Jan-Feb;15(1):23-34. This study demonstrates the healing effects of Chrysalin on diabetic foot ulcers.
Carney DH, Olszewska-Pazdrak B. Expert Opin Pharmacother. 2008 Oct;9(15):2717-26. This review discusses the future potential of rusalatide acetate in tissue repair.
Ryaby JT, Sheller MR, Levine BP, Bramlet DG, Ladd AL, Carney DH. J Bone Joint Surg Am. 2006 Nov;88 Suppl 3:132-9. This review highlights the role of TP508 in promoting angiogenesis and tissue regeneration.
The FDA and EMA granted Orphan Drug Designation to TP508 for the treatment of acute radiation syndrome, providing market exclusivity and other benefits.
Chrysalis was selected to participate in the 2024 Respiratory Innovation Summit at the American Thoracic Society Meeting.
The FDA has approved Chrysalis to begin human clinical trials for Chrysalin™ (TP508) for treating acute lung failure.
Fife C, Mader JT, Stone J, Brill L, Satterfield K, Norfleet A, Zwernemann A, Ryaby JT, Carney DH. Wound Repair Regen. 2007 Jan-Feb;15(1):23-34. This study demonstrates the healing effects of Chrysalin on diabetic foot ulcers.
Carney DH, Olszewska-Pazdrak B. Expert Opin Pharmacother. 2008 Oct;9(15):2717-26. This review discusses the future potential of rusalatide acetate in tissue repair.
Ryaby JT, Sheller MR, Levine BP, Bramlet DG, Ladd AL, Carney DH. J Bone Joint Surg Am. 2006 Nov;88 Suppl 3:132-9. This review highlights the role of TP508 in promoting angiogenesis and tissue regeneration.
The FDA and EMA granted Orphan Drug Designation to TP508 for the treatment of acute radiation syndrome, providing market exclusivity and other benefits.